Sygnis SA (WSE:SYG)
1.350
+0.020 (1.50%)
Last updated: Jun 10, 2026, 9:00 AM CET
Sygnis Revenue
Sygnis had revenue of 2.32M PLN in the quarter ending March 31, 2026, with 266.42% growth. This brings the company's revenue in the last twelve months to 13.02M, up 69.58% year-over-year. In the year 2025, Sygnis had annual revenue of 11.34M with 15.66% growth.
Revenue (ttm)
13.02M
Revenue Growth
+69.58%
P/S Ratio
2.91
Revenue / Employee
1.18M
Employees
11
Market Cap
37.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.34M | 1.53M | 15.66% |
| Dec 31, 2024 | 9.80M | -10.23M | -51.08% |
| Dec 31, 2023 | 20.03M | -8.48M | -29.73% |
| Dec 31, 2022 | 28.51M | 25.11M | 739.70% |
| Dec 31, 2021 | 3.39M | 600.08K | 21.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.83B |
| Diagnostyka | 2.51B |
| Synektik Spólka Akcyjna | 794.94M |
| Voxel | 583.14M |
| BioMaxima | 60.90M |
| Read-Gene | 16.54M |
| Pharmena | 1.61M |
| Nestmedic | 1.02M |